GTHX G1 Therapeutics Inc.

G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It engages in developing novel, small-molecule therapies to target significant unmet needs to treat cancer.

As of 07/01/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/17/2017
Outstanding shares:  42,705,532
Average volume:  1,450,660
Market cap:   $210,965,328
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BF0QXG9
Valuation   (See tab for details)
PE ratio:   -1.29
PB ratio:   2.20
PS ratio:   8.73
Return on equity:   -170.88%
Net income %:   -708.20%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy